New Migraine Prevention Medication Guidelines for Adults

Updated Guidelines for Migraine Prevention in Adults

The joint practice guideline update aims to help clinicians navigate an expanding array of treatment options for a chronic brain disease that affects millions. According to guideline author Tamara Pringsheim, MD, MSc, of the University of Calgary, the updated standards address both episodic and chronic forms of the condition. People with episodic migraine experience headaches on fewer days per month, whereas chronic migraine involves headaches on 15 or more days a month, with at least eight of those days exhibiting specific migraine features, according to the guideline data.

Thresholds for Starting Preventive Treatments

To curb headache frequency and severity, the updated guideline specifies that preventive treatments should be offered to individuals under distinct clinical circumstances. According to the document, clinicians should recommend these therapies to patients who experience four or more migraine days per month, four or more moderate to severe headache days per month, or whose condition impairs their ability to work and complete daily tasks.

Rebecca C. Burch, MD, of the University of Vermont Larner College of Medicine noted that the research demonstrates numerous medication types can successfully prevent attacks and reduce symptoms. If a specific medication fails to yield results, clinicians and patients have alternative classes to explore, ranging from established oral drugs to newer injectable options administered monthly or once every three months.

Endorsements and Clinical Impact

The guideline has received formal endorsement from the American Academy of Family Physicians, underscoring its broad applicability across both specialized neurology practices and primary care settings. American Headache Society President Matthew S. Robbins, MD, emphasized that newer treatment options have revolutionized care, while American Academy of Neurology President Natalia S. Rost, MD, MPH, FAAN, FAHA, highlighted the collaborative effort to improve brain health outcomes for individuals living with the neurological disease.

Frequently Asked Questions

What is the difference between acute and preventive migraine medications?

According to the guideline, acute medications help stop headaches and associated symptoms while they are happening, whereas preventive medications are taken consistently—usually daily or monthly—to avert symptoms before they start.

Who qualifies for preventive migraine treatment under the new update?

The guideline states that preventive treatments should be offered to adults who have four or more migraine days per month, four or more moderate to severe headache days per month, or whose symptoms interfere with work and daily activities.

What types of medications are included in the updated guidance?

The update covers both established treatments, such as certain blood pressure-lowering drugs and antidepressants, and newer classes of targeted migraine preventives delivered orally or via injections.